Association of a vascular endothelial growth factor polymorphism with the development of bronchopulmonary dysplasia in Japanese premature newborns

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Fujioka, Kazumichi ^a   Shibata, Akio ^a   Yokota, Tomoyuki ^a   Koda, Tsubasa ^a   Nagasaka, Miwako ^a   Yagi, Mariko ^a   Takeshima, Yasuhiro ^a   Yamada, Hideto ^a   Iijima, Kazumoto ^a   Morioka, Ichiro ^a  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A;

ARTICLE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HUMAN; LUNG DYSPLASIA; MALE; NEWBORN; PATHOPHYSIOLOGY; PREMATURITY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

BRONCHOPULMONARY DYSPLASIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897038691     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04459     Document Type: Article

References (61)

1. Stevenson, D. K. et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol. 179, 1632-1639 (1998).
2. Shepherd, E. G. et al. An interdisciplinary bronchopulmonary dysplasia program is associated with improved neurodevelopmental outcomes and fewer rehospitalizations. J Perinatol. 32, 33-38 (2012).
3. Tang, J. R. et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 287, L344-351 (2004).
4. Egawa, T. et al. Ureaplasma urealyticum and Mycoplasma hominis presence in umbilical cord is associated with pathogenesis of funisitis. Kobe J Med Sci. 53, 241-249 (2007).
5. Kinsella, J. P., Greenough, A. & Abman, S. H. Bronchopulmonary dysplasia. Lancet. 367, 1421-1431 (2006).
6. Bhandari, V. et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics. 117, 1901-1906 (2006).
7. Lavoie, P. M., Pham, C. & Jang, K. L. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics. 122, 479-485 (2008).
8. Wang, H. et al.Agenome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics. 132, 290-297 (2013).
9. Takahashi, H. & Shibuya, M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 109, 227-241 (2005).
10. Breier, G., Albrecht, U., Sterrer, S. & Risau, W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 114, 521-532 (1992).
11. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380, 435-439 (1996).
12. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380, 439-442 (1996).
13. Shifren, J. L., Doldi, N., Ferrara, N., Mesiano, S. & Jaffe, R. B. In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. J Clin Endocrinol Metab. 79, 316-322 (1994).
14. Clark, D. E., Smith, S. K., Sharkey, A. M. & Charnock-Jones, D. S. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod. 11, 1090-1098 (1996).
15. Andraweera, P. H., Dekker, G. A., Laurence, J. A. & Roberts, C. T. Placental expression of VEGF family mRNA in adverse pregnancy outcomes. Placenta. 33, 467-472 (2012).
16. Lassus, P. et al. Vascular endothelial growth factor and angiogenin levels during fetal development and in maternal diabetes. Biol Neonate. 84, 287-292 (2003).
17. Voelkel, N. F., Vandivier, R. W.& Tuder, R. M. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 290, L209-221 (2006).
18. Maeda, S. et al. Analysis of intrapulmonary vessels and epithelial-endothelial interactions in the human developing lung. Lab Invest. 82, 293-301 (2002).
19. Fujita, M. et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol. 93, 2162-2170 (2002).
20. Grover, T. R. et al. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 284, L508-517 (2003).
21. Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 163, 1723-1729 (2001).
22. Goodman, G. et al. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr. 112, 67-72 (1988).
23. Bhatt, A. J. et al. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. AmJ Respir Crit Care Med. 164, 1971-1980 (2001).
24. Watson, C. J., Webb, N. J., Bottomley, M. J. & Brenchley, P. E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 12, 1232-1235 (2000).
25. Shahbazi, M. et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 13, 260-264 (2002).
26. Renner, W., Kotschan, S., Hoffmann, C., Obermayer-Pietsch, B. & Pilger, E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 37, 443-448 (2000).
27. Yamamori, M. et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun. 325, 144-150 (2004).
28. Yagi, M. et al. VEGF 936C. T is Predictive of Threshold Retinopathy of Prematurity in Japanese Infants with Gestational Age of 30 weeks or less. Res Rep Neonatol. 1, 5-11 (2011).
29. Cooke, R. W.,Drury, J. A.,Mountford, R.& Clark, D. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci. 45, 1712-1715 (2004).
30. Salmon, J. Fetal alcohol spectrum disorder: New Zealand birth mothers' experiences. Can J Clin Pharmacol. 15, e191-213 (2008).
31. Itabashi, K. et al. Revised Birth size standards by gestational age for Japanese neonates. J Jpn Pediatr Soc. 114, 1271-1293 (In Japanese) (2010).
32. Shennan, A. T., Dunn, M. S., Ohlsson, A., Lennox, K. & Hoskins, E. M. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 82, 527-532 (1988).
33. Hankinson, J. The role of VEGF in lung function. The University of Manchester Library, 2013. 1-223 (2013).
34. Morohashi, K., Takada, T., Omori, K., Suzuki, E. & Gejyo, F. Vascular endothelial growth factor gene polymorphisms in Japanese patients with sarcoidosis. Chest. 123, 1520-1526 (2003).
35. Awata, T. et al. A common polymorphism in the 59-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 51, 1635-1639 (2002).
36. Yamamori, M. et al. VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int J Med Sci. 5, 80-86 (2008).
37. Tahara, T. et al. Effect of polymorphisms in the 39-untranslated region (39-UTR) of VEGF gene on gastric pre-malignant condition. Anticancer Res. 29, 485-489 (2009).
38. Masago, K. et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci. 100, 1917-1922 (2009).
39. Sakaeda, T. et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit. 30, 497-503 (2008).
40. Hadchouel, A. et al. Matrix metalloproteinase gene polymorphisms and bronchopulmonary dysplasia: identification of MMP16 as a new player in lung development. PLoS One. 3, e3188 (2008).
41. Rodriguez, S., Gaunt, T. R. & Day, I. N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 169, 505-514 (2009).
42. Barrett, J. C., Fry, B.,Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 21, 263-265 (2005).
43. Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 41, 1149-1160 (2009).
44. Wang, N., Akey, J. M., Zhang, K., Chakraborty, R. & Jin, L. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. Am J Hum Genet. 71, 1227-1234 (2002).
45. Silvers, K. M., Gibson, A. T., Russell, J. M. & Powers, H. J. Antioxidant activity, packed cell transfusions, and outcome in premature infants. Arch Dis Child Fetal Neonatal Ed. 78, F214-219 (1998).
46. Van Marter, L. J. et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics. 105, 1194-1201 (2000).
47. Young, T. E., Kruyer, L. S., Marshall, D. D.& Bose, C. L. Population-based study of chronic lung disease in very low birth weight infants in North Carolina in 1994 with comparisons with 1984. The North Carolina Neonatologists Association. Pediatrics. 104, e17 (1999).
48. Peacock, J. L., Marston, L., Marlow, N., Calvert, S. A. & Greenough, A. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr Res. 71, 305-310 (2012).
49. Kraybill, E. N., Runyan, D. K., Bose, C. L. & Khan, J. H. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr. 115, 115-120 (1989).
50. Bhandari, A. & Bhandari, V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics. 123, 1562-1573 (2009).
51. Madurga, A., Mizikova, I., Ruiz-Camp, J. & Morty, R. E. Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 305, L893-905 (2013).
52. Acarregui, M. J., Penisten, S. T., Goss, K. L., Ramirez, K. & Snyder, J. M. Vascular endothelial growth factor gene expression in human fetal lung in vitro. Am J Respir Cell Mol Biol. 20, 14-23 (1999).
53. Lassus, P. et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med. 164, 1981-1987 (2001).
54. Levesque, B. M. et al. Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity. Neonatology. 104, 56-64 (2013).
55. Lambrechts, D. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 34, 383-394 (2003).
56. Nyholt, D. R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 74, 765-769 (2004).
57. Chumakov, I. et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA. 99, 13675-13680 (2002).
58. Fallin, D. et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res. 11, 143-151 (2001).
59. Stoll, M. et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 36, 476-480 (2004).
60. Kwinta, P. et al. Genetic risk factors of bronchopulmonary dysplasia. Pediatr Res. 64, 682-688 (2008).
61. Hadchouel, A. et al. Identification of SPOCK2 as a susceptibility gene for bronchopulmonary dysplasia.AmJ Respir Crit Care Med. 184, 1164-1170 (2011).